Validation of [18F]FES for Imaging of Brain Estrogen Receptors (NCT01842217) | Clinical Trial Compass
TerminatedNot Applicable
Validation of [18F]FES for Imaging of Brain Estrogen Receptors
Stopped: Not enough participants
Netherlands3 participantsStarted 2013-11
Plain-language summary
Validation of \[18F\]-FES for imaging of estrogen receptors in the brain
The primary objective of the study is to determine if \[18F\]-FES Positron Emission Tomography (PET) can be used to quantify the estrogen receptor expression in the human brain.
Who can participate
Age range18 Years ā 65 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Female
* Age \> 18 years
* For postmenopausal women: at least 1 year after menopause
* For premenopausal women: a regular menstruation
* Signed written informed consent
Exclusion Criteria:
* Use of estrogen receptor ligands, such as tamoxifen or fulvestrant
* History of ER-positive malignancies or breast cancer
* Use of any contraceptive drugs (pill, injections or implanted)
* For postmenopausal women: (history of) estrogen replacement therapy
* Pregnancy
* History of removal of the ovaries and/or the uterus
* Current systemic diseases
* Major metabolic diseases (e.g. diabetes, hyper- or hypothyroidism)
* Somatic, organic or neurological disorders
* Recent participation in a scientific research study (\<1 year) involving radiation
* Claustrophobia
* Presence of materials in the body that can be magnetized, like: pacemaker, metallic implants/prostheses, metal fragments, shunts, artificial heart valves, vascular clips, fixed hearing aid, tattoos containing metal, hair implants, artificial dentures
What they're measuring
1
Quantification of estrogen receptors in the human brain